Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 3/20 | 1.00 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | KMO | O15229 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19046507 | 0.90 | ASIC3 (0.81) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL284286 | 0.84 | ASIC3 (0.71) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL28218682 | 0.81 | ASIC3 (0.68) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL29406194 | 0.81 | ASIC3 (0.68) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL27904874 | 0.81 | ASIC3 (0.68) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL28049525 | 0.81 | ASIC3 (0.67) | ASIC3MIFKMONPC1RAB9A | |
| SCHEMBL558077 | 0.81 | ASIC3 (0.68) | ASIC3MIFKMOSMN1; SMN2KMT2A | |
| SCHEMBL18731738 | 0.79 | ASIC3 (0.65) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL29730373 | 0.79 | ASIC3 (0.65) | ASIC3MIFKMOADORA2AADORA1 | |
| SCHEMBL17697185 | 0.79 | ASIC3 (0.65) | ASIC3MIFKMOADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107739370-A | The preparation method and purposes of pyrrolones BRD4 protein inhibitors | 中国药科大学 | 2018-02-27 | — | — | CN | claimed |
| CN-112010844-B | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2023-07-25 | — | — | CN | disclosed |
| CN-113105475-B | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3670520-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2022-01-12 | — | — | EP | disclosed |
| CN-113105475-A | Inhibitors of bruton's tyrosine kinase and methods of use thereof | 詹森药业有限公司 | 2021-07-13 | — | — | CN | disclosed |
| CN-107739370-B | Preparation method and application of pyrrolidone BRD4 protein inhibitor | 中国药科大学 | 2021-03-30 | — | — | CN | disclosed |
| CN-112010844-A | Preparation method and application of N- (pyrimidine-2-yl) coumarin-7-amine derivative as protein kinase inhibitor | 中国药科大学 | 2020-12-01 | — | — | CN | disclosed |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-13 | — | — | US | disclosed |
| EP-3712145-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING SUCH COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2020-09-23 | — | — | EP | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1973897-A2 | SUBSTITUTED PYRYMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | Bayer HealthCare AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007075650-A2 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | BAYER HEALTHCARE AG (DE) | 2007-07-05 | — | — | WO | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
| US-3950525-A | BRONCHODILATION, 4-HYDROXY-6-ARYL PYRIMIDINES | PFIZER INC. (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | ASIC3 3500/4885MIF 3315/4885KMO 2542/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | ASIC3 1435/4885MIF 4879/4885KMO 932/4885 |
| US-10822348-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | ASIC3 4303/4885MIF 2221/4885KMO 4039/4885 |
| US-10800792-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, MYLK2 | ASIC3 4269/4885MIF 2213/4885KMO 3809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.